
Bracco Diagnostics and Subtle Medical have secured the CE Mark for their collaborative AI-powered software AiMIFY for brain MRI.
AiMIFY uses AI technology to increase the contrast enhancement of brain MRI scans up to twice the level typically achieved with a dose of gadolinium-based contrast agents (GBCAs), according to the two firms.
The companies will begin to prepare to market AiMIFY in Europe, with efforts continuing throughout 2025 and a phased commercial rollout between late 2025 and early 2026, they said.